Profile Previews

Get a glimpse into our company and investor data—powered by the PitchBook Platform

GenetaStix

2000 FOUNDED
M&A STATUS
M&A LATEST DEAL TYPE
Description

Producer of antibody therapeutics. The company engages itself in the production of human monoclonal antibody therapeutics to fight cancer, infectious and autoimmune diseases and other life threatening and debilitating diseases.

Ownership Status
Acquired/Merged
Financing Status
Formerly VC-backed
Primary Industry
Biotechnology
Other Industries
Therapeutic Devices
Acquirer
Primary Office
  • 780 Montague Expressway
  • Suite 303
  • San Jose, CA
  • United States
Request full access to PitchBook

You’re viewing a free company profile from the PitchBook Platform. To explore GenetaStix’s full profile, request a free trial.

GenetaStix Valuation and Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
2. Merger/Acquisition 26-Jul-2007 00.00 Completed Generating Revenue
1. Early Stage VC (Series A) 09-Nov-2000 00.00 00.00 00.000 Completed Startup
To view this company’s complete deal history including valuation and funding, request access »

GenetaStix Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate ($) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion
Price
% Owned
Series A 0,000,000 00.000000 00.00 00.00 00.00 00 00.00 00.000
To view this company’s complete Cap Table, request access »

GenetaStix Former Investors (2)

Investor Name Investor Type Holding Investor Since Participating Rounds Board
Seat
Contact
Info
Fortune Venture Investment Group Venture Capital Minority 000 0000 000000 0
Kenson Ventures Venture Capital Minority 000 0000 000000 0

GenetaStix Executive Team (2)

Name Title Board
Seat
Contact
Info
Li Zhu Ph.D Chief Executive Officer, President, Lead Scientist Board Member & Co-Founder
S. Benjamin Hua Ph.D Vice President, Research & Co-Founder